Network pharmacology approach and experimental verification of Danzhi Xiaoyao Powder for breast cancer treatment based on UHPLC-Q-Orbitrap HRMS

Danzhi Xiaoyao Powder (DZXYP), a classical formulation in traditional Chinese medicine (TCM), exhibits promising effects in suppressing the proliferation and migration of breast cancer (BC) cells; nonetheless, its detailed pharmacological mechanisms have not yet been fully elucidated. This study sought to explore the mechanism by which DZXYP targets the PI3K/AKT/mTOR signaling pathway to treat BC through serum pharmacology, network pharmacology, and in vitro/in vivo experiments.